Newest indication OPDIVO® 120MG

OPDIVO® is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT)

Please see the full prescribing information and all indications.